DMBT1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P10813(DMBT1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P10813(DMBT1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The DMBT1 (Deleted in Malignant Brain Tumors 1) antibody targets a protein encoded by the *DMBT1* gene, which is implicated in innate immunity, epithelial differentiation, and cancer biology. Initially identified as a tumor suppressor in brain tumors, DMBT1 is a secreted glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) superfamily. It contains multiple SRCR domains, CUB domains, and a zona pellucida (ZP) motif, enabling interactions with pathogens, immune cells, and extracellular matrix components. DMBT1 is highly expressed in mucosal tissues (e.g., salivary glands, lungs, gastrointestinal tract), where it functions as a pattern recognition receptor, binding to bacteria, viruses, and fungi to modulate immune responses.

In cancer, *DMBT1* is frequently downregulated or deleted in gliomas, colorectal, and other carcinomas, suggesting a role in tumor suppression. Paradoxically, it may also promote cancer progression in certain contexts by enhancing cell adhesion or survival. DMBT1 antibodies are vital tools for studying its localization, expression levels, and functional roles. They are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore its involvement in inflammation, tissue repair, and carcinogenesis. Commercial antibodies may vary in specificity (monoclonal vs. polyclonal) and epitope recognition, necessitating validation for experimental reproducibility. Research using DMBT1 antibodies continues to clarify its dual roles in homeostasis and disease, offering potential as a diagnostic biomarker or therapeutic target.